TRANSTHERA BIOSCIENCES
TransThera Biosciences is a biotech company that focuses on the discovery and development of small-molecule new drugs. Its research and business strategies zero in clear unmet medical needs in oncology and inflammatory diseases through internal research and open innovation. The company was founded in 2016 and is headquartered in Nanjing, Jiangsu.
TRANSTHERA BIOSCIENCES
Social Links:
Industry:
Biotechnology Life Science Oncology
Founded:
2016-01-01
Address:
Nanjing, Jiangsu, China
Country:
China
Website Url:
http://www.transtherabio.com
Total Employee:
51+
Status:
Active
Contact:
025-86901057
Email Addresses:
[email protected]
Total Funding:
147.93 M USD
Technology used in webpage:
SPF Alibaba HiChina DNS Alibaba Cloud MailBox
Similar Organizations
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Walden Biosciences
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease.
Current Employees Featured
Founder
Investors List
Trinity Innovation Fund
Trinity Innovation Fund investment in Series D - TransThera Biosciences
Honest Capital
Honest Capital investment in Series D - TransThera Biosciences
CPE
CPE investment in Series D - TransThera Biosciences
GP Healthcare Capital
GP Healthcare Capital investment in Series D - TransThera Biosciences
China Structural Reform Fund
China Structural Reform Fund investment in Series D - TransThera Biosciences
Winfast Holding
Winfast Holding investment in Series D - TransThera Biosciences
Co-Stone Venture Capital
Co-Stone Venture Capital investment in Series D - TransThera Biosciences
China Merchants Venture Capital
China Merchants Venture Capital investment in Series D - TransThera Biosciences
Sixty Degree Capital
Sixty Degree Capital investment in Series D - TransThera Biosciences
Morningside Ventures
Morningside Ventures investment in Series A - TransThera Biosciences
Official Site Inspections
http://www.transtherabio.com
Unable to get host informations!!!
More informations about "TransThera Biosciences"
Home - TransThera Sciences (Nanjing), Inc. — Transformative …
Our non-oncology pipeline focuses on large unmet medical needsand hard-to-treat inflammatory and cardiovascular diseases. Inthese therapeutic areas, we have four small molecule …See details»
TransThera Announced Global Phase 3 Clinical Trial for ...
Mar 8, 2024 TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced that the randomized, controlled, global …See details»
CRC Oncology – Caring | Sharing | Supporting
Dec 18, 2019 For more information, please visit www.transtherabio.com. CRC Oncology is a contract research organization (CRO) focused on reshaping the global landscape of innovative …See details»
Nanjing TransThera Biosciences Co. Ltd. - VentureRadar
Mar 9, 2024 "Nanjing TransThera Biosciences Co. Ltd. is an innovation platform company focused on discovery and development of small molecule new drugs. Therapeutic areas of …See details»
TransThera Receives Fast Track Designation from FDA for its Core ...
Nov 3, 2021 TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit …See details»
TransThera Biosciences Announces IND Approval from FDA for …
Dec 17, 2019 TT-00920 marks the company's second innovative drug candidate entering global clinical development. For more information, please visit www.transtherabio.com. SOURCE …See details»
TransThera Announces that the IND Application of TT-01488, a …
Feb 18, 2022 TransThera Sciences (Nanjing), Inc. ("TransThera") announced that the U.S. Food and Drug Administration ("FDA") approved the Investigational New Drug ("IND") application of …See details»
TransThera Receives Fast Track Designation from FDA for its
Nov 3, 2021 TransThera Sciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its phase II stage product TT-00420 for the treatment of …See details»
TransThera Biosciences Announces IND Approval from FDA for
TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based in Nanjing, China, announced today that the U.S. Food and Drug Administration (FDA) has granted the …See details»
TransThera Biosciences Lead Product TT-00420 Granted Orphan …
NANJING, China, Nov. 7, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug …See details»
CRC Oncology – Caring | Sharing | Supporting
Dec 2, 2020 About CRC Oncology CRC Oncology is a contract research organization (CRO) focused on reshaping the global landscape of innovative drugs and therapies for cancer …See details»
TransThera announces collaboration with Roche to evaluate TT …
May 26, 2021 TransThera Biosciences Co. Ltd. ( "TransThera" ), a clinical stage biotechnology company dedicated to developing innovative therapeutics across oncology, cardiovascular, …See details»
LG Chem Life Sciences and TransThera Biosciences Announce …
Aug 17, 2020 LG Chem enters an exclusive license agreement with TransThera for development and commercialization of TransThera’s TT-01025.See details»
LG Chem Life Sciences and TransThera Biosciences Announce …
Aug 17, 2020 LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, …See details»
LG Chem Life Sciences and TransThera Biosciences ... - Business Wire
Dec 1, 2020 LG Chem announces U.S. FDA clearance of IND for TransThera’s TT-01025, a novel inhibitor for the treatment of NASH.See details»
TransThera announces collaboration with Roche to evaluate TT …
May 26, 2021 TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit …See details»
TransThera Receives Fast Track Designation from FDA for its Core ...
NANJING, China, Nov. 3, 2021 /PRNewswire/ -- TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat CholangiocarcinomaSee details»
TransThera Announces that the IND Application of TT-01488, a …
Feb 18, 2022 TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit …See details»